Medication Access in America

The Multi-Billion Dollar Companies of the Drug Supply Chain

Articularis Healthcare March 30-31, 2021

Madelaine T. Feldman MD, FACR.

Coalition of State Rheumatology Organizations- President Clinical Instructor/Assis. Prof. of Medicine – Tulane Medical School The Rheumatology Group

MadelaineFeldman@gmail.com

or

"Waiting for Godot"

Drug Pricing Reform in America


Access

Obstacles to Access

What Are We Talking About?

What Do We Do About it?

MISC.







The Bad





For Example...

Martin Shkreli is best known for raising the price of Daraprim, an HIV drug by 5,000 percent when he was CEO of Turing Pharmaceuticals

"We raised the price from \$1,700 per bottle to \$75,000," Shkreli wrote to a contact in August. Should be a very handsome investment for all of us."



Spent \$2 million on a one-of-a-kind Wu Tang Clan album



Mo Bad...

"Generic Drug Cartel"

"This is most likely the largest cartel in the history of the United States"

- Lawsuits on price-fixing involving at least sixteen companies and 300 generic drugs
- Generic makers blamed
 - Industry consolidations,
 - [Federally] mandated plant closures,
 - Elimination of unprofitable generic drug product lines
- The complaint alleges "that the drug companies knew their conduct was illegal and avoided communicating with one another in writing."

More Bad...

In 2003 the most widely used self-injectables for RA were priced around \$1,000/mo


(Boston Business Journal Dyke Hendrickson Oct 20, 2003)

Today the same self-injectables have a list prices greater than \$6,000/mo

Other Forces
At Play Here



Who are some of the Players in the Drug Distribution System?







What Do PBMs do?


"Pharmacy benefit managers, or PBMs, are companies that **manage prescription drug benefits** on behalf of health insurers, Medicare Part D drug plans, large employers, and other payers."

- Adjudicate pharmacy claims
- Patient cost share
- Pharmacy network
- Construct/maintain formulary
- SITE of CARE



Who are the Big 3 PBMs?


- Express Scripts (ESI) (#22 Fortune 500 -2018)
- CVS Caremark (CVS Health) (#5 Fortune 500-2018)
- Optum Rx (United Health) (#7 Fortune 500 2018)



Express Scripts covers 83 million. (Express Scripts Corporate Overview, downloadable at http://lab.express-scripts.com/about.) CVS Caremark covers approximately 90 million. (CVS Health At A Glance, https://www.cvshealth.com/about/facts-and-company-information.)



PBM Market Share, by Total Equivalent Prescription Claims Managed, 2020



- 1. Excludes Drug Channels Institute estimates of double-counted network claims for mail choice claims filled at CVS retail pharmacies.
- 2. Includes Cigna claims, which fully transitioned to Express Scripts by the end of 2020. Includes Ascent Health Services, which includes Kroger Prescription Plans and a partial year of Prime Therapeutics.
- 3. Excludes Drug Channels Institute estimates of 2020 claims for which Ascent Health Services handled rebate negotiations and pharmacy network contracting.
- 4. Figure includes some cash pay prescriptions that use a discount card processed by one of the 6 PBMs shown on the chart.

Source: The 2021 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers, Drug Channels Institute, Exhibit 92. Total equivalent prescription claims includes claims at a PBM's network pharmacies plus prescriptions filled by a PBM's mail and specialty pharmacies. Includes discount card claims. Note that figures may not be comparable with those of previous reports due to changes in publicly reported figures of equivalent prescription claims. Total may not sum due to rounding.





Pharmacy Benefit Managers

Vertical Business Relationships Among Insurers, PBMs, and Specialty Pharmacies, 2019



Source: Drug Channels Institute research. AllianceRx Walgreens Prime is jointly owned by Prime Therapeutics and Walgreens Boots Alliance.

This chart appears as Exhibit 77 in The 2019 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers, Drug Channels Institute. Available at http://drugch.nl/pharmacy





Vertical Integration-PBMs/Insurance Companies AND CLINICS



- PBMs claim to save billions for our health care system
 - Designing formularies based on "negotiated discounts"
 - Secret kickback package based on list price & market share
 - Utilization Management Tools "Employers want them"
 - Keep patients on the most profitable drugs
 - Many Employers have no idea what they are signing
 - More affordable pharmacy channels
 - Encouraging use of generics & affordable brands
 - Higher priced and brands preferred



Health Subcommittee -Energy and Commerce 2019





PBMs Ultimately Determine

What - Constructing the Formulary

Whem - Step therapy, Non-Med Switch

Where - Pharmacy network, Site of Care

How Much — Copay, Co-insurance

Breaking Down the Drug/Money/Services Flow



SIMPLIFIED VERSION **Drug Flow** Manufacturer Placement Services **Cash Flow** Rebate + FEES Rebate \$\$\$\$\$\$\$\$\$ Kickbacks) Reimbursement Health + Admin Fee **Plans** Manage Drug **PBM Wholesaler** Program **Share of Rebate** Reinbutsenent & Drug Bridge Drug Payment Network. Dispense Drug **Patients Employers** Copay/Coinsurance **Pharmacies** CSRO

If An Expensive Drug Is Not on the Formulary...

No Matter How Great It Is...

No One Takes It



Why Do Manufacturers Fight For Preferred Placement?

- Benefits Of Preferred Placement for Drug Makers
 - Step Therapy Fail your drug first
 - Non Medical Switching Switch to your drug
 - Excludes Competitors to your drug
 - Exclusionary contracts
 - Performance contracts



What Determines Preferred Placement?

- Efficacy?
- Safety?
- Lowest list price?

Guess again.....



The Rebate Story...

Cam't Forset About
The Fees,

What About the Aggregators?



How it works...


• "Bidding war" - Preferred Place on Formulary

Largest price concession (Rebate + Fees)

Best chance at the preferred spot.

- Drug utilization determined by
 - Rebates/Fees
 - NOT Doctor Patient Relationship
 - Not Lowest List Price Of Drugs





Rebate+Fees Bids








Pharmacy Benefit Manager











The Equation

Total Formulary Rebate =

List Price x % Rebated x # Scripts filled

- 1. List price of the drug
- 2. % Rebate promised
- 3. # Scripts filled (Market share)

An Increase In Any One Of These Variables Better Chance At Preferred Placement



Which Drug Has The Best Bid?

	Drug A	Drug B	Drug C
List Price	\$2,000/mo	\$4,000/mo	\$5,000/mo
Rebate %	60%	40%	40%
Formulary Rebate	\$1,200	\$1,600	\$2,000



PBMs Claim They "SAVE" Billions Of Dollars Through Their Preferred Formularies (& Use of UM tools)

Calculating "Savings" the PBM way

- 2 Identical Dresses -
 - One is list priced at \$1000 and the other at \$100
 - Both are offered at 50% off list price

Which Dress Would PBMs Pick for Their Dress Formulary??

PBMs would pick the \$1000 dress

PBM Industry Report - Greater Use Of UM Tools Can Generate \$1T In Savings Over Next



Where do the "Savings" Go?

- Lower premiums?
- Lower co-pays / coinsurance amounts?
- Lower list prices of medications?

Hmmmm.....



Who are the Big 3 PBMs?

- Express Scripts (ESI) (#22 Fortune 500 -2018)
- CVS Caremark (CVS Health) (#5 Fortune 500-2018)
- Optum Rx (United Health) (#7 Fortune 500 2018)

SOURCES: Insurance companies start to bring PBM in-house: CVS Health's PBM business could be under threat. Forbes. July 28, 2015. http://www.forbes.com/sites/greatspeculations/2015/07/28/insurance-companies-start-to-bring-pbm-in-house-cvs-healths-pbm-business-could-be-under-threat/#69b4f3d23df2. Accessed January 10, 2017; Britschgi C. Pharmacy benefit managers could be in legislative crosshairs. Watchdog.org, http://watchdog.org/285187/pharmacy-benefit-managers-legislative-crosshairs/. January 3, 2017.

Express Scripts covers 83 million. (Express Scripts Corporate Overview, downloadable at https://lab.express-scripts.com/about.) CVS Caremark covers approximately 90 million. (CVS Health At A Glance, https://www.cvshealth.com/about/facts-and-company-information.)



What About Competition?



Manufacturers Compete for the Preferred Spot...



BUILDING A HOUSEWINNER= Lowest Bidder

COMPETITION
DRIVES
PRICES
DOWN

COMPETITION DRIVES PRICES UP



SELLING A HOUSEWINNER= Highest Bidder

OUR DRUG DISTRIBUTION SYSTEM

- PBMs receive rebates/fees based on a % of the list price of the medicine.
- These price concessions can be over 50% of the list price.
- This creates a perverse incentive for HIGHER PRICED MEDICINES, not lower, because the HIGHER PRICED MEDICINE can provide the larger rebate /fee package.



The Higher the LIST PRICE, The Higher the...

- Administration fees Manufacturers pay admin fees that are often based on list price
- Price protection rebate- List price increase above a ceiling
 - Triggers additional rebate payments.
- **Specialty pharmacy fees** some fees are % of list price
- Vendor fees ???



FROM EXPRESS SCRIPTS CONTRACT (Axios.com)

For sake of clarity, **Rebates do not include**, for example,

Manufacturer Administrative Fees;

- Inflation payments;
- **Product discounts or fees related to the procurement** of prescription drug inventories by ESI Specialty Pharmacy or the Mail Service Pharmacy;
- **Fees** received by ESI from pharmaceutical manufacturers for care **management/ services** provided with the dispensing of products;
- Other fee-for-service arrangements whereby pharmaceutical manufacturers generally report the fees paid to ESI or its whollyowned subsidies for services rendered as **"bona fide service fees"** (collectively, **"Other Pharma Revenue"**)

Such laws and regulations, as well as ESI's contracts with pharmaceutical manufacturers, generally prohibit ESI from sharing any such "bona fide service fees" earned by ESI, whether wholly or

in part, with any ESI client.



Invoice <u>Date</u>	Type of Contract	Formulary <u>Rebate</u>	Admin Fee	Price Protection Rebate	<u>Total</u>
Jan-16	Commercial	\$1,612.50	\$24,963.90	\$5,689.26	\$32,265.66
Jan-16	Medicare	\$450	\$2,652.13	\$5,184.14	\$8,286.57
2/1/16: kale	o increases Ev	zio list price f	rom \$937.50 to	\$4,687.50	
Apr-16	Commercial	\$7,125.00	\$129,517.29	\$4,951,923.90	\$5,088,566.19
May-16	Commercial	\$9,937.50	\$137,162.51	\$2,266,092.01	\$2,413,192.02
Dec-16	Commercial	\$4,312.50	\$56,395.65	\$977,873.22	\$1,038,581.37
Dec-16	Medicare	\$3,375	\$12,468.56	\$219,218.80	\$235,062.36
	Total	\$26,812.50	\$363,160.04	\$8,425,981.33	\$8,815,954.17
http://www.pharn	nacybenefitconsultant	s.com/rx-alerts/time	e-to-determine-if-your-p	bm-is-hiding-rebates/	

The Higher the LIST PRICE, The Higher the...

- Administration fees Manufacturers pay admin fees that are often based on list price
- Price protection rebate- List price increase above a ceiling
 - Triggers additional rebate payments.
- **Specialty pharmacy fees** some fees are % of list price
- Vendor fees ???

MOST IMPORTANT -Patient Cost Patient Co-insurance % Is Based On List Price

Co-insurance Based on List Price

- 20% -Prices \$10K/mo or more
- Copay cards from the manufacturer Pay patient cost share
- Helps patients chronic diseases also by reducing deductible

PBMs Thought "WAIT JUST A MINUTE!"

"How can we make money on this?"

Accumulator Adjustment Program

A utilization management tool that **disallows** money paid by a drug manufacturer in the form of a **copay card** to **count toward the deductible/OOP costs** of the patient.

"Deductible Double Dipping"

(collects deductible amount from both manufacturer and patient)

CVS Caremark

Plan Design Optimization: leverages the
 value of copay cards to enhance program
 savings by increasing the copay to optimize the
 value of the manufacturer program.



Deductible Double Speak

- High/Low
- Individual
- Family
- In/Out of-network
- HSA
- Max Out of Pocket





Copay Cards Are Bad!

Medical Side Doesn't Offer Co-pay Assistance

Copay Cards

Entice Patients, Hook Patients

On Expensive Medications



"Congratulations...your cholesterol is lower than your copay."

How Often are Copay Cards used When There is a Lower Priced Generic?

- An IQVIA analysis of claims data from 2013-2017
- The use of copay cards on those brand drugs is

0.4%

of total commercial market volume

This is due at least in part to:

Formulary exclusions and generic substitution

Which have curtailed copay cards for brands that have lost exclusivity



Who are Most Affected by Accumulators

Chronic Disease Patients

- Economically forced off their prescription without consequence
- Patients taking \$\$ specialty drugs
 - Single source drugs no lower cost alternative
 - Co-insurance % of list price
- Patients with High Deductible Plans



PBM Market Fails On

Accountability

Conflict of Interests

Fiduciary Responsibility

Transparency



How Do They Get Away With This?

"Safe Harbor"
From the
Anti-Kickback Statute





Who Regulates PBMs?

Federal

- HHS/CMS Part D Rebate Rule Redo PCMA (lawsuit)
- Federal Trade Commission maybe never met a PBM they didn't like
- DOJ Allowed mergers
- Congress Senate and House Bills "Safe Step ACT"
- States (ERISA issues)*
 - Legislation CSRO.info/map Rutledge v PCMA (SCOTUS)
 - Board of Pharmacy,
 - Insurance commissioners
 - Attorney General





HOME CONFERENCES MEMBERSHIP

FELLOWS RESOURCES NEWS ABOUT

Q search U privacy w donate contact

Home » Advocacy » Legislative Map Tool

ADVOCACY

Federal Advocacy

State Advocacy Legislative Map Tool

Action Center

Correspondence

Legislative Map Tool

Welcome to the CSRO Legislative Map

This page houses CSRO's legislative map tool, which will allow you to learn about existing and pending step therapy, nonmedical switching, accumulator adjustment program, and uniform prior authorization laws in your state and at the federal level.

Using the Map

1. SELECT YOUR STATE For Federal issues click the "DC" 2. SELECT YOUR ISSUE

legislature.

See what utilization management reform laws are on the books in your state, what their provisions are, how they apply, and what issues are pending in the state

3. NO LEGISLATION?

Find out how you can get involved. and what resources CSRO offers to help you change that.

4. COMMUNICATE WITH US!

We want to hear from you. Let us know what can be improved, what questions you have, and what issues you would like to see detailed on the map.

Leaflet | Legislation data @ CSRO



Donate to CSRO

Find our work beneficial? You can make a difference and directly impact the rheumatology community by making a donation. To do so, please contact info@csro.info.

Disclaimer

The state and federal policy environment is constantly changing. Every effort is made to keep the information presented here comprehensive and up to date. Please contact us if you experience any issues, broken links, out of date information, etc.

The information presented in this tool is presented for informational purposes, and should not be considered legal advice. CSRO and its representatives are not rendering legal services through the information published within the tool, and the information presented should not be used as a substitute for professional services.

FIND YOUR STATE

CSRO.info/map

Ising the Map

. SELECT YOUR STATE

or Federal issues click the "DC"

2. SELECT YOUR ISSU


See what utilization management reform laws are on the books in your state, what their provisions are, how they apply, and what issues are pending in the state legislature.

3. NO LEGISLATION?

Find out how you can get involved, and what resources CSRO offers to help you change that.

4. COMMUNICATE WITH US!

We want to hear from you. Let us know what can be improved, wha questions you have, and what issues you would like to see detailed on the map.



☐ Fiscal Note ✓ Votes

LEGISLATORS LEGISLATION VIDEOS SCHEDULES & CALENDARS COMMITTEES DIRECTORY

Bill History

♥ Video Summary

02/08/2021

FIND MY LEGISLATOR MY BILLS

HB 0619 by *Rudder

◆ Show Co-Prime Sponsors

(SB 1397) by *Swann

◆ Show Co-Prime Sponsors

Show Caption Text

Insurance Companies, Agents, Brokers, Policies - As introduced, requires an insurer to include cost sharing amounts paid by the enrollee, or on behalf of the enrollee by another person, when calculating an enrollee's contribution to an applicable cost sharing requirement. - Amends TCA Title 56, Chapter 7.

LIDOCAO	
HB0619 ACTIONS	DATE
Passed Senate as amended, Ayes 30, Nays 0	04/27/2021
Senate adopted Amendment (Amendment 1 - SA0414)	04/27/2021
Senate substituted House Bill for companion Senate Bill.	04/27/2021
Received from House, Passed on First Consideration	04/22/2021
Engrossed; ready for transmission to Sen.	04/21/2021
Passed H., Ayes 91, Nays 0, PNV 0	04/21/2021
H. Placed on Regular Calendar for 4/21/2021	04/15/2021
Placed on cal. Calendar & Rules Committee for 4/15/2021	04/14/2021
Rec. for pass; ref to Calendar & Rules Committee	04/06/2021
Placed on cal. Insurance Committee for 4/6/2021	03/31/2021
Rec. for pass by s/c ref. to Insurance Committee	03/30/2021
Placed on s/c cal Insurance Subcommittee for 3/30/2021	03/24/2021
Assigned to s/c Insurance Subcommittee	02/20/2021
P2C, ref. to Insurance Committee	02/11/2021
Intro., P1C.	02/10/2021

2 Amendments

SB1397 ACTIONS	DATE
Companion House Bill substituted	04/27/202
Placed on Senate Regular Calendar for 4/27/2021	04/23/202
Recommended for passage with amendment/s, refer to Senate Calendar Committee Ayes 9, Nays 0 PNV 0	04/21/202
Placed on Senate Commerce and Labor Committee calendar for 4/21/2021	04/14/202
Reset on Final calendar of Senate Commerce and Labor Committee	04/09/202
Placed on Senate Commerce and Labor Committee calendar for 4/7/2021	04/07/202
Action deferred in Senate Commerce & Labor Committee to 4/7/2021	04/06/202
Placed on Senate Commerce and Labor Committee calendar for 4/6/2021	03/30/202
Action deferred in Senate Commerce and Labor Committee to 4/6/2021	03/30/202
Placed on Senate Commerce and Labor Committee calendar for 3/30/2021	03/24/202
Passed on Second Consideration, refer to Senate Commerce and Labor Committee	02/22/202
Introduced, Passed on First Consideration	02/11/202
Filed for introduction	02/11/202

Senate

Meet the Lt. Governor

House of Representatives

Meet the Speaker

Filed for introduction

Joint Committee

HOME CONFERENCES MEMBERSHIP ADVOCACY FELLOWS RESOURCES NEWS ABOUT

Home » Advocacy » Action Center



Welcome to the CSRO Action Center

With so many concerns to track, legislators rely on you to raise the profile of pressing issues. This page houses CSRO's engagement platform, which allows you to communicate directly with your legislators. Advocacy is important, but we are also mindful of your time. Our tool allows you to participate in grassroots advocacy with minimal time expenditure.

TENNESSEE - ACCUMULATOR PROGRAMS

Contact your legislators and urge them to support HB 619

Accumulator Adjustment Programs, also known as "out-of-pocket protection" or "coupon adjustment" programs, are a utilization management tool being used by insurers and pharmacy benefit managers. These alternative cost-sharing structures prevent the value of co-pay assistance from being applied towards a patient's deductible as an out-of-pocket expense. In the past, once the value of a patient's co-pay assistance was depleted, a patients' deductible had been met, ensuring they could afford otherwise financially inaccessible drugs. Now, PBMs are double dipping, preventing patients from being able to afford medically necessary drugs.

What does the bill do?

HB 619 requires any payments made by, or on behalf of a patient, to be counted towards their deductible or other cost-sharing obligations.

What can you do?

CSRO encourages you to make your voice heard by contacting your Tennessee state legislators in support of HB 619. You may do so using the tool located to the right of this message. We highly encourage personalization of the message provided personalized messages have a higher degree of visibility.

Compose Your Message

- · State Senator
- · State Representative

Subject

Support HB 619 - Stop Deductible Double Dippir

Message Body

I am writing to request your support for HB 619.

As a rheumatologist providing care to Tennesseans with musculoskeletal

Enter Your Info

Your Information

Send me text alerts

Home Information

ZIP Code * Enter Zip for City and State

Business Information

Enter Zip for City and State



HOME CONFERENCES MEMBERSHIP ADVOCACY FELLOWS RESOURCES NEWS ABOUT

Sign Up for Alerts

ZIP Code

Find Legislation

Find Officials

View and search for legislation,

Elected Officials O Candidates

Enter your information below to sign

Action Center

Welcome to the CSRO Action Center

With so many concerns to track, legislators rely on you to raise the profile of pressing issues. This page houses CSRO's engagement platform, which to communicate directly with your legislators. Advocacy is important, but we are also mindful of your time. Our tool allows you to participate in graadvocacy with minimal time expenditure.

Federal Campaigns State Campaigns

LOUISIANA - ACCUMULATORS

Please consider personalizing your message - lawmakers are inundated with email in the virtual environment and personalized messages have a much greater chance of being seen directly by lawmakers. Contact your legislators and urge them to support SB 94 Accumulator...



WISCONSIN - ACCUMULATOR PROGRAMS

ease consider personalizing your message - personalized messages have much greater chance of being seen directly by legislators. Contact your egislators and urge them to support SB 215Accumulator Adjustment ograms, also known as "out-of-pocket protection" or...



FEDERAL - STEP THERAPY

Contact your legislators and urge them to support \$464What does the bill do?Step therapy has become an impediment to appropriate care for patients across specialties. \$464 reforms the step therapy process to ensure patients get the right treatment at the right.



ILLINOIS - ACCUMULATOR BAN REPEAL

CSRO opposes HB 2948What's the issue? Accumulator Adjustment Programs, also known as "out-of-pocket protection" or "coupon adjustment" programs, are a new utilization management tool being used by insurers and pharmacy benefit managers. These alternative cost-sharing...



FLORIDA - NON-MEDICAL SWITCHING

Contact your legislators and urge them to support SB 1612 Florida patients can have coverage of their medications restricted at any time. No laws in Florida prohibit insurers from changing coverage during the course of the olan year - when patients are locked into...



MICHIGAN - ACCUMULATOR PROGRAMS

Contact your legislators and urge them to support HB 4353 Accumulator Adjustment Programs, also known as "out-of-pocket protection" or "coupon adjustment' programs, are a new utilization management tool being used by insurers and pharmacy benefit managers. These alternative...



TENNESSEE - ACCUMULATOR PROGRAMS

ontact your legislators and urge them to support HB 619 Accumulator djustment Programs, also known as "out-of-pocket protection" or "coupe djustment" programs, are a utilization management tool being used by surers and pharmacy benefit managers. These alternative...



RHODE ISLAND - ACCUMULATOR PROGRAMS

Contact your legislators and urge them to support H5438 Accumulator Adjustment Programs, also known as "out-of-pocket protection" or "coupl adjustment" programs, are a utilization management tool being used by nsurers and pharmacy benefit managers. These alternative...



NEW MEXICO - ACCURAGINATION & DRAW

TRANSPARENC

Adjustment Programs, a adjustment' programs, a

SOUTH DAKOTA

Contact your legislators

by insurers and pharmar

FLORIDA - ACCI

Contact your legislators

Accumulator Adjustmen

tool being used by insure

TEXAS - ACCUN

Contact your legislators

ccumulator Adjustmen

anagement tool being

KANSAS - STEP

CALIFORNIA - STEP THEF ease consider personalizing your

MISSOURI - STEP THERAI

ch greater chance of being seen o



tact your legislators and urge the ents across specialties, HB 677 i

N OREGON - STEP THERAPY AUTHORIZATION the bills do? Step therapy & pnor au





NEW JERSEY - STEP THEI





IOWA - NON-MEDICAL SW





ontact your legislators and urge th

stment' programs, are a utilization management loof being us

laws in Uklanoma pronibit insurers from changing coverage during the course of the plan year - when patients are locked...



OREGON - ACCUMULATOR PROGRAMS

Contact your state legislators and urge them to support SB 560 Accumulator Adjustment Programs, also known as "out-of-pocket protection" or "coupon adjustment" programs, are a utilization managemen tool being used by insurers and pharmacy benefit managers. These,



ARKANSA

herapy law th

Arkansas' Act

NEBRASK

Contact your leg

natients across

ensure patients

NEBRASK

IOWA - AC

PRICING

Adjustment Pr

adjustment" o

CONNECT

Contact your

Adjustment P

by insurers an

MARYLAN

Accumulator A

protection" or

KENTUCK

Contact your I

MASSACHUSETTS

ontact your legislators and ur atients can have coverage of t aws in the state prohibits insurnedications that are successful



ARKANSAS - ACCUM **PROGRAMS**

Contact your legislators and urç Adjustment Programs, also kno adjustment" programs, are a uti insurers and pharmacy benefit



NEW YORK - NON-M

Contact your legislators and urg No laws in New York prohibit in course of the plan year - when,



TEXAS - NON-MEDIC

Contact your legislators and urc exas who are stable on their m ear formulary restrictions that wever, no laws protect Texas



ALABAMA - ACCUM

Contact your legislators and urg 492Accumulator Adjustment Pr protection" or "coupon adjustma nanagement tool being used b



OHIO - ACCUMULAT

Contact your legislators and urg Adjustment Programs, also kno adjustment" programs, are a ne by insurers and pharmacy benefit managers. These



OREGON - STEP THERAPY & PRIOR AUTHORIZATION

Contact your legislators and urge them to support SB 44 & HB 2517 What do the bills do? Step therapy & prior authorization have become an npediment to appropriate care for patients across specialties. These bills reform prior authorization.



NEW JERSEY - STEP THERAPY

ontact your legislators and urge them to support A4815 & S3051 What do the bills do? Step therapy has become an impediment to appropriate care for patients across specialties. These bills reform the step therapy process o ensure patients get the right.



NEW YORK - ACCUMULATOR PROGRAMS

Contact your legislators and urge them to support A1741 & S5299Accumulator Adjustment Programs, also known as "out-of-pocket protection" or "coupon adjustment" programs, are a utilization management tool being used by insurers and pharmacy benefit managers. These...



IOWA - NON-MEDICAL SWITCHING

Contact your legislators and urge them to support SF 178 & HF 656 lowa patients can have coverage of their medications restricted at any time. No laws in lowa prohibit insurers from forcing stable patients from medications that are successfully managing..



PENNSYLVANIA - ACCUMULATOR PROGRAMS

Contact your legislators and urge them to support SB 196 Accumulator Adjustment Programs, also known as "out-of-pocket protection" or "coupon adjustment' programs, are a utilization management tool being used by nsurers and pharmacy benefit managers. These alternative.



OKLAHOMA - ACCUMULATOR PROGRAMS

Contact your legislators and urge them to support SB 92 & HB 2678 Accumulator Adjustment Programs, also known as "out-of-pocket protection" or "coupon adjustment" programs, are a utilization management tool being used by insurers and pharmacy benefit managers. These...



ARIZONA - STEP THERAPY

Contact your legislators and urge them to support SB 1270 What does the bill do? Step therapy has become an impediment to appropriate care for patients across specialties. SB 1270 reforms the step therapy process to ensure patients get the right treatment at the right...



MASSACHUSETTS - ACCUMULATOR **PROGRAMS**

Contact your legislators and urge them to support \$.644Accumulator djustment Programs, also known as "out-of-pocket protection" or "coupon adjustment" programs, are a new utilization management tool being used by insurers and pharmacy benefit managers. These alternative.



ARIZONA - PRIOR AUTHORIZATION

Contact your legislators and urge them to support HB 2621 What does the



YAY! West Virginia PBM House Bill 2263,

- "Requires pharmacy benefit managers to be licensed by the State,
- Report on network adequacy,
- Protects pharmacists from telling patients about lower costs alternatives,
 prevents clawbacks and spread pricing,
- Patients cost sharing for their medication will be calculated at the point-of-sale and based on a price equal to 100% of the rebate that PBMs collect*
- Allows for patients to choose their own pharmacy
- *Rebate aggregators



Recent Legislation

Accumulators

- 3 bills signed into law: KY, OK, AR
 - TN -has yet to be transmitted to the Governor.
- 24 state bills introduced this year
 - 15 bills still pending (CT, FL, IA, LA, MA, MI, NV, NY, OH, OR, PA, RI, TN, TX, WI)
 - 6 bills have died (AL, MD, MN, NE, NM, SD).
 - AL PBM legislation is still alive but was stripped of accumulator provision and otherwise watered down.
- We are working with the Primary Immune Foundation to involve the Pennsylvania Rheumatology Association directly in advocating for the state's accumulator legislation.



Step Therapy

- 2 states have passed laws this year: AR, NE, soon AZ
 - Active bills remain in: CA, MA, MO, NJ, OR, PA, TN, & RI.
 - Of these bills we believe that CA, NJ, and OR are likely to pass this session.
- Non-medical Switching no signed bills yet
- Active legislation : FL, IA, MA, MN, NY, OH, OK, PA, TX.
 - Of these bills, FL, IA, MN, and OK are effectively dead.
 - MA, NY, OH, and TX remain in play. NY and TX best odds
- Cigna \$500 Switching Incentive
- Dr. M. Feldman is co-authoring an op-ed with NORM on this issue.
- CSRO co-signed the attached letter authored by AARDA opposing the practice.

State Drug Affordability Legislation

- Limits on Pricing vs Reimbursement
 - Oregon
- Maryland Affordability Board



Obstacles to "Buy and Bill"

Federal/State Obstacles

Commercial Obstacles



Federal/State Obstacles

☐ Self- Administered Drug List (SAD List)

Loss of Access to Part B – (not paid for)

- □ Part B Drug Pricing Reforms
- ☐ State Drug Affordability legislation/boards



SAD List — Only Part D Formulation Will Be Paid For-Once on the SAD List....

Medications with Dual Formulations

Part B – Provider administered

Part D – Self administered

What Determines Which Drugs Move To The SAD List??

☐ Fifty Percent Rule

Greater than 50% of usage is Part D

Drug is Self-Administered *by the patient a majority of the time

Definition of "By the patient" according to CMS guidelines

*Medicare Beneficiaries And Not Other Individuals

(that is, spouses, friends, or other care givers are not considered the patient)

■ Interval of Dosing

≥ 4 weeks more likely to be Provider Administered

What We Did...

•CSRO Met With:

- First Coast Services Options (FCSO FL & Puerto Rico),
 Palmetto (both Carolina's and Virginia's), Noridian (California & Nevada)
- Worked with GHLF to survey patients -

broad issues with the CAD list

- Did they self-inject as defined by MC?
 Recalculate Part D usage presented to MACs Working
 Group
- Met with CMS representative discussed Stelara and the control

Part B Drug Pricing Reform

- □ Part B Demonstration Project Created An Uproar
- ☐ International Pricing Index IPI
- Most Favored Nation MFN

□ HR.3 - ? fate



H.R. 3 - The Lower Drug Costs Now Act

- Title I 3 "buckets" of drugs for the new negotiation 125 drugs highest net spending in the US.
- Those selected for negotiation would get a "maximum fair price," capped at 120% of average international price.
- Providers reimbursed at maximum fair price + 6% instead of ASP plus 6%. Pt. coinsurance would be assessed against the maximum fair price as well.



H.R. 3 – The Lower Drug Costs Now Act

- Title III Part D OOP cost-sharing
- \$2,000 annual cap on OOP spending
- Circumstances allow beneficiaries to spread out that \$2,000 over the course of the year



Latest Part B Issue

- Consolidated Appropriations Act Congress is ordering CMS to change pricing (for reimbursement) Cimzia and Orencia
- 2017 OIG report \$.5 billion was loss in 2018 and 2019
- OIG: "CMS did not concur with our recommendation. ... CMS stated this could negatively affect beneficiary access to medically necessary drugs as well as increase the cost of these drugs....further analysis on the cost, policy, and operational implications would need to be conducted to determine whether such a change in law would be appropriate."

CMS Response to CSRO

- "We also appreciate your question regarding the changes required as a result of the Consolidated Appropriations Act, 2021.
- Section 405 of the CAA, 2021 was explicit with the date (7/1/2021) CMS is to implement those provisions.
- CMS is planning to issue program instruction in accordance with the authority provided under statute."



PhRMA's Part B Proposal

- A "market-based adjustment" (rebate) would be paid to MC if a drug's commercial net price was lower than its average sales price.
- The 10% of Part B beneficiaries without any supplemental insurance would have a flat \$20 copay instead of the current 20% coinsurance.
- No change to the buy-and-bill system (should not lower physician reimbursement)
 - •The rebates would be paid retroactively by the company directly to the government.
- ***Note that commercial net prices are not usually lower than ASPs, but where this

is the case, the difference is significant.



Commercial Obstacles to "Buy and Bill" for

Provider Administered Medications

- ☐ White Bagging, Brown Bagging and Clear Bagging
- Formulary Exclusions, Step Therapy and Non-medical Switching
- ☐ Mandated Site of Care Change Health plans/ Vivio

Pharmacy Benefit Managers





Health Insurance Companies



Pharmacy Benefit Managers





Specialty

Physician Administered Medications

<u>Pharmacy</u>

✓ Formulary Construction

✓ Utilization Management Tools

https://www.healio.com/news/rheumatology/20191113/formulary-construction-in-america-perfectly-legal-and-perfectly-wrong

Why Integrate The Medical And Pharmacy Side – According To HR Executives?

"According to a J.P. Morgan survey, half of top human resources executives don't believe that integrating medical and drug benefits will drive overall healthcare savings. Here are two notable quotes:"

"There's too much money to be made.

They're not offering integrated services to give up revenue."

"More ways to hide money."

Consequences

- ☐ Buy and Bill Channel Management
 - White Bagging From Specialty Pharmacy Owned By The PBM

- ☐ Buy and Bill Utilization Management
 - Formularies with Exclusions, Step Therapy and Non-Medical Switching
- ☐ Mandated Change in Site of Care to Plan Owned Infusion Centers



Vivio

Carves out Specialty Drugs for Self Funded Businesses

"Our Formula To Reduce Your Spend & Take Better Care Of Your Employees And Their Families"

"Achieve Better Outcomes For Your Employees While Lowering Your Current Spend 25-35%"



Vivio Sounds Too Good To Be True to Employers

- Non-medical Switching
- White Bagging
- Mandated Biologic Tapering
- Mandated Change In Site Of Care



What's a Rheumatologist To Do?

With Sufficient Thrust Pigs Fly Just Fine!!



Formulary Construction in America

"Perfectly Legal"


and

"Perfectly Wrong"

NolaRheum@gmail.com



The Transparency Problem



"Let's never forget that the public's desire for transparency has to be balanced by our need for concealment."

